Stoke Therapeutics (STOK) Equity Average: 2022-2025
Historic Equity Average for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $321.5 million.
- Stoke Therapeutics' Equity Average rose 35.43% to $321.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $321.5 million, marking a year-over-year increase of 35.43%. This contributed to the annual value of $194.3 million for FY2024, which is 12.83% up from last year.
- Latest data reveals that Stoke Therapeutics reported Equity Average of $321.5 million as of Q3 2025, which was down 6.13% from $342.5 million recorded in Q2 2025.
- Over the past 5 years, Stoke Therapeutics' Equity Average peaked at $342.5 million during Q2 2025, and registered a low of $150.0 million during Q1 2024.
- For the 3-year period, Stoke Therapeutics' Equity Average averaged around $228.4 million, with its median value being $202.0 million (2023).
- Per our database at Business Quant, Stoke Therapeutics' Equity Average fell by 24.77% in 2024 and then skyrocketed by 93.09% in 2025.
- Stoke Therapeutics' Equity Average (Quarterly) stood at $194.5 million in 2022, then dropped by 14.51% to $166.3 million in 2023, then skyrocketed by 38.66% to $230.6 million in 2024, then spiked by 35.43% to $321.5 million in 2025.
- Its last three reported values are $321.5 million in Q3 2025, $342.5 million for Q2 2025, and $289.5 million during Q1 2025.